Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Two cloned macaques named Zhong Zhong and Hua Hua at the non-human-primate research facility under the Chinese Academy of Sciences (CAS). Photo: Xinhua / Jin Liwang via Getty Images
Two biotechnology stories from China captured the world’s attention this past week:
- First, the WSJ reported that a group of doctors in Hangzhou have been using CRISPR gene-editing in experiments with cancer patients. Elsewhere, medical scientists are far more cautious about using the technology in humans.
The concern: Clinical trials are not always well regulated around the world. The gene editing activity in China not only flouts the safety-first standard in developed countries and exploits desperate patients, it misses an opportunity to learn from carefully designed clinical trials.
- Second, more than two decades after Dolly the sheep was cloned, scientists in China reported they had cloned the first primate. It required new techniques and involved dozens of failures before two infant monkeys were finally born with perfect copies of the genes in their cells, creating enormous opportunities for comparative research.
What it means: These results reinforce the possibility of using human clones for research. Still, the risks involved in cloning for human reproduction are simply too great, as the many failed attempts at monkey cloning make clear.
The bottom line: These developments are a reminder that the U.S. is no longer the sole player. However, science is not a zero-sum game. Along with the need for appropriate regulation, the question now is whether the U.S. is in a position to collaborate and contribute new information. In that sense, the less flashy National Institutes of Health announcement of a $190 million commitment to support work on new tools for gene editing is ultimately the bigger news this week.
Jonathan D. Moreno is the David and Lyn Silfen University Professor of Ethics at the University of Pennsylvania.